This trial did not specify a primary end point and compared multiple different outcomes at multiple time points.371 The SAVE RCT (Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease) randomized 2717 patients with established cardiovascular or cerebrovascular disease (but not within the first 90 days after a stroke except for minor strokes) and moderate to severe OSA to CPAP versus usual care without CPAP and found no reduction of vascular events, including stroke, in patients treated with CPAP over a mean follow-up of Thus, the routine screening for OSA of all patients with AIS for the secondary prevention of cardiovascular events or death is not recommended at this time. Several ongoing National Institutes of Health funded RCTs are further investigating the effects of CPAP in patients with AIS and OSA (NR018335, NS099043). See Table LXXXVI in online Data Supplement 1. Routine testing for antiphospholipid antibodies is not recommended for patients with ischemic stroke who have no other manifestations of the antiphospholipid syndrome and who have an alternative explanation for their ischemic event such as atherosclerosis, carotid stenosis, or atrial fibrillation. III: No Benefit C-LD Recommendation reworded for clarity from 2014 Secondary Prevention. COR and LOE amended to conform with ACC/AHA 2015 Recommendation Classification System. See Table XCV in online Data Supplement 1 for original wording. Routine screening for hyperhomocysteinemia among patients with a recent ischemic stroke is not indicated. III: No Benefit C-EO Recommendation reworded for clarity from 2014 Secondary Prevention. COR and LOE amended to conform with ACC/AHA 2015 Recommendation Classification System. See Table XCV in online Data Supplement 1 for original wording. 6.3.2. Echocardiography (Continued) COR LOE New, Revised, or Unchanged Powers et al 2019 Guidelines for Management of AIS e393 6.6. Antithrombotic Treatment 6.6.1. 